What is claimed is:

1. A combination for treating a Hedgehog-related cancer comprising a Smoothened inhibitor and a PI3 kinase inhibitor, wherein the Smoothened inhibitor is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl] –amide, N-[4-chloro-3-(5-dimethylamino-lH-benzoimidazol-2-yl)- phenyl]-3,5-dimethoxy-benzamide, 2-[(R)-4-(6-benzyl-4,5-dimethyl- pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof.

2. The combination of claim 1, wherein the cancer is a medulloblastoma.

3. The combination of claims 1 or 2, wherein the cancer is from a resistant tumor.

4. The combination of claims 1-3, wherein the PI3 kinase inhibitor is selected from - methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3- dihydro-imidazo[4,5-c]quinolin-l-yl)-phenyl]-propionitrile, 8-(6-methoxy-pyridin-3-yl)-3-methyl- 1 -(4-piperazin- 1 -yl-3-trifluoromethyl- phenyl)-l,3-dihydro-imidazo[4,5-c]quinolin-2-one, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)- 4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof.

5. A combination for treating a Hedgehog-related cancer comprising a Smoothened inhibitor and a Gli inhibitor, wherein the Smoothened inhibitor is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl] –amide, N-[4-chloro-3-(5-dimethylamino-lH-benzoimidazol-2-yl)- phenyl]-3,5-dimethoxy-benzamide, 2-[(R)-4-(6-benzyl-4,5-dimethyl- pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof.

6. The combination of claim 5, wherein the cancer is a medulloblastoma.

7. The combination of claims 5 or 6, wherein the cancer is from a resistant tumor.

8. The combination of claims 5-7, wherein the Gli inhibitor is selected from GANT61 and GANT58.

9. The combination of claims 5-7, wherein the Gli inhibitor is selected from zerumbone, zerumbone epoxide, staurosporinone, 6-hydroxystaurosporinone, arcyriaflavin C, and 5,6- dihydroxyarcyriaflavin A, physalin F, and physalin B.

10. A combination for treating a Hedgehog-related cancer comprising a Smoothened inhibitor and a statin, wherein the Smoothened inhibitor is 2-Methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6- dimethyl-morpholin-4-yl)-pyridin-3-yl] –amide, N-[4-Chloro-3-(5-dimethylamino-1H-benzoimidazol-2-yl)- phenyl]-3,5-dimethoxy-benzamide or 2-[(R)-4-(6-Benzyl-4,5-dimethyl- pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-propan-2-ol.

11. The combination of claim 10, wherein the cancer is a medulloblastoma.

12. The combination of claims 10 or 11, wherein the cancer is from a resistant tumor.

13. The combination of claims 10-12, wherein the statin is selected from pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, and pitavastatin.

# CLAIMS

1. Use of a Smoothened inhibitor and a PI3 kinase inhibitor, wherein the Smoothened inhibitor is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, N-[4-chloro-3-(5-dimethylamino-1H-benzoimidazol-2-yl)-phenyl]-3,5-dimethoxy-benzamide, 2-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a Hedgehog-related cancer.

2. Use according to claim 1 wherein the PI3 kinase inhibitor is selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof.

3. Use of a Smoothened inhibitor and a Gli inhibitor, wherein the Smoothened inhibitor is 2-methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, N-[4-chloro-3-(5-dimethylamino-1H-benzoimidazol-2-yl)-phenyl]-3,5-dimethoxy-benzamide, 2-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Hedgehog-related cancer.

4. Use according to claim 3, wherein the Gli inhibitor is selected from GANT61 and GANT58.

5. Use according to claim 4, wherein the Gli inhibitor is selected from zerumbone, zerumbone epoxide, staurosporinone, 6-hydroxystaurosporinone, arcyriaflavin C, and 5,6-dihydroxyarcyriaflavin A, physalin F, and physalin B.

6. Use of a Smoothened inhibitor and a statin, wherein the Smoothened inhibitor is 2-Methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, N-[4-Chloro-3-(5-dimethylamino-1H-benzoimidazol-2-yl)-phenyl]-3,5-dimethoxy-benzamide or 2-[(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-propan-2-ol, in the manufacture of a medicament for the treatment of Hedgehog-related cancer.

7. Use according to claim 6, wherein the statin is selected from pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, and pitavastatin.

8. A use according to any one of claims 1-7, wherein the cancer is a medulloblastoma.

9. A use according to any one of claims 1-7, wherein the cancer is from a resistant tumor.